Bifidobacterium breve MCC1274: Cognitive Function, the Gut–Brain Axis, and Human Evidence

What Is MCC1274?

Bifidobacterium breve MCC1274, or Bifidobacterium breve strain MCC1274, is also called Bifidobacterium breve A1 in earlier papers. MCC1274 and A1 refer to the same specific strain. Unlike probiotics studied mainly for bowel regularity or general gut health, this strain has been investigated for cognitive function and the gut–brain axis.

Probiotic effects are highly strain-specific. A product labeled only as Bifidobacterium breve cannot be assumed to share MCC1274's research findings; both the species name and the MCC1274 strain designation matter. MCC1274 is a human-derived strain originally isolated from the infant gut. Its origin alone does not prove that it benefits adults; what makes it noteworthy is that this exact strain has been tested in multiple randomized human trials of cognitive function.

What Functions Are Being Studied?

Judging from the research on MCC1274 itself, the stronger signals are concentrated in immediate memory, delayed memory and visuospatial ability. Results were more mixed for global cognition, with weaker evidence for attention and executive function. Safety data in the short and medium term are relatively stable, However, there is still a lack of human evidence for treating mild cognitive impairment and preventing Alzheimer's disease.

Three important randomized trials in humans

2019: 121 people, 12 weeks

This was a randomized, double-blind, placebo-controlled study of 121 older adults with subjective sensory memory decline, with 117 completing the trial. When comparing all subjects together, cognitive scores improved over time in both the MCC1274 and placebo groups. However, there was no significant difference in overall cognitive changes between the two groups. This is a negative result that cannot be ignored when evaluating this strain.

After further stratifying by baseline status, those with lower starting RBANS scores showed greater improvements in immediate memory and MMSE total scores. This finding suggests that MCC1274 may be more suitable for people who already have mild cognitive decline, rather than having the same effect on all healthy people. However, this was a stratified or subgroup analysis and the strength of the evidence was lower than the prespecified primary endpoint of the entire population.

2020: 80 people, 16 weeks

Researchers screened 315 people and selected 80 participants with suspected mild cognitive decline; their average age was about 61. Participants were randomized to MCC1274 or placebo. The treatment group received 2 × 10¹⁰ CFU (20 billion CFU) per day for 16 weeks. This remains the most favorable human trial of MCC1274 to date.

RBANS was used to assess immediate memory, visuospatial/constructional ability, language, attention, and delayed memory, as well as an overall score. After 16 weeks, the MCC1274 group's advantage over placebo in the RBANS total score was +11.3 points (95% confidence interval: +6.7 to +15.8; p<0.0001).

• Immediate memory: between-group difference +9.2 points, 95% confidence interval +5.1 to +13.3, p<0.0001
• Delayed memory: between-group difference +11.0 points, 95% confidence interval +6.6 to +15.3, p<0.0001
• Visual spatial and structural abilities:Difference between groups +11.4 points, 95% confidence interval +6.8~+16.0, p<0.0001
• Language:The difference between groups is +3.5 points, p≈0.064, which does not meet the commonly used statistical significance standard.
• Attention:The difference between groups is about +0.5 points, p≈0.74, no significant improvement

These data support memory and spatial abilities rather than overall improvements in cognitive abilities, nor should MCC1274 be considered a concentration enhancer. The JMCIS scale in the same study had p≈0.052 in the intention-to-treat analysis, which did not meet conventional significance criteria; Only the per-protocol completers analysis reached significance, p≈0.036. Even in this most positive trial, there was no consistent conclusion across cognitive scales.

These 80 people were not ordinary people with completely normal cognition, but a group of people with low RBANS scores screened out of 315 people. Therefore, the result of +11.3 points cannot be directly generalized to young adults with normal cognitive functions.

2022: 130 people, 24 weeks

The longer study included 130 people aged 65 to 88 with suspected mild cognitive impairment. The same 20 billion CFU per day for 24 weeks. The primary analysis included 115 people, 55 in the MCC1274 group and 60 in the placebo group.

At 24 weeks, the ADAS-Jcog score improved by approximately −1.34 points in the MCC1274 group and by approximately −1.36 points in the placebo group. Between-group p≈0.789; the total MMSE score increased by approximately +2.61 points and +2.63 points respectively, and between-group p≈0.923. Neither measure of global cognition showed MCC1274 was superior to placebo, failing to replicate the significant improvement in global cognition seen in the 2020 trial.

The research is not without positive signs. There was an inter-group difference in the orientation ability sub-item of ADAS-Jcog, p≈0.021; Some subgroups with lower baseline cognition also showed advantages or trends in improvement on items such as time orientation, writing, and the revised MMSE. Because these are component or subgroup results, they cannot be equated with the primary endpoint of the overall scale.

MRI brain atrophy index

The 2022 study also performed MRI and VSRAD analyzes on 89 people, 42 in the MCC1274 group and 47 in the placebo group. After 24 weeks, the global gray matter atrophy range index changed by approximately −0.07 in the MCC1274 group and approximately +0.16 in the placebo group, with p≈0.013 between groups. This result suggests that the MCC1274 group has made less progress in this indicator, which is a signal worthy of continued research.

Other MRI indices did not simultaneously yield significant results. There were no significant between-group differences in medial temporal lobe or hippocampus-related VOI Z-scores, Other VOI range indicators also did not reach significance; among people with more obvious baseline brain atrophy, some results only showed a trend of p≈0.055~0.086. Therefore, it is accurate to understand that there was a positive signal in a single whole-brain gray matter measure, rather than that MCC1274 has been shown to prevent brain shrinkage.

How the Human Evidence Fits Together

What the three studies present is not simply effective or ineffective, but a set of conditional results: the signal of cognitive improvement is real; Stronger signals are concentrated in people who already have mild cognitive decline and in specific areas such as memory and visuospatial ability; Results are affected by subject selection, assessment scales, and trial design, and independent reproducibility is currently insufficient.

How MCC1274 may affect the brain

The research logic of MCC1274 is not to allow a certain component to directly enter the brain to act on neurons, but to have an effect through the gut-brain axis. Possible pathways include: strains change microbial metabolites as they pass through the intestine, interact with the intestinal immune system, and then affect systemic inflammation and inflammatory signals in the brain. Regulates microglia and hippocampal function, ultimately affecting memory. The complete causal chain comes primarily from mouse and cell studies and has not been directly confirmed in humans.

Microglia, neuroinflammation and Aβ

A 2017 animal study used a model of Aβ-induced Alzheimer's disease-like cognitive impairment. After oral administration of B. breve A1 to mice, Cognitive decline was improved, and abnormal expression of multiple inflammation- and immune-response-related genes in the hippocampus was suppressed. This provides early support for the hypothesis that MCC1274 protects memory by reducing neuroinflammation.

Microglia are an important part of the immune system in the brain. When abnormally activated for a long time, they can release inflammatory cytokines, active substances and other immune mediators, Further damage to synapses and neurons. A recurring direction in animal studies is microglial activation and decreased neuroinflammation.

Follow-up studies using APP knock-in mouse models capable of progressive amyloid pathology showed memory impairment, Aβ production or deposition, and reduced microglial activation. Such animal results can only serve as mechanistic clues. Randomized human trials have not yet demonstrated that MCC1274 can reduce amyloid PET signals, Improvements in cerebrospinal fluid Aβ or phosphorylated tau also did not demonstrate a reduction in Alzheimer's disease incidence.

Acetic acid and tryptophan metabolites

Bifidobacteria can produce metabolites such as acetic acid. Early animal experiments found that plasma acetate increased after ingestion of MCC1274; Bacterial components and acetic acid itself can also reproduce cognitive protection to some extent. The resulting acetic acid affects the intestinal barrier, immune and inflammatory signaling, A candidate mechanism that then acts indirectly on the brain, but this process has not yet been fully validated in humans.

Recent research has also focused on tryptophan metabolites, especially indole derivatives such as indole-3-lactic acid. These substances may be involved in antioxidant, intestinal barrier, immune regulation, and AhR receptor signaling. Mouse metabolome study finds MCC1274 It can change some plasma metabolites that may have neuroprotective significance, but it is still in the stage of mechanism exploration.

May be effective without permanent colonization

Probiotics do not necessarily have to permanently become the dominant bacteria in the intestinal tract to produce physiological effects. Human trials in 2022 did not observe significant large-scale changes in overall gut microbiota composition. One possible explanation is that MCC1274 continues to produce metabolites and interact with the gut immune system as it passes through the gut each day, rather than reconstituting the entire gut microbiota.

This also shows that it is different from the traditional concept of probiotics that regulate defecation, and is closer to probiotics targeting the gut-brain axis. Studies of other Bifidobacterium breve strains on constipation, immunity, or allergy cannot be directly attributed to MCC1274.

Dose, Duration, and Product Identification

The most representative dose currently used in cognitive human trials is daily 2 × 10¹⁰ CFU, which is 20 billion CFU per day. Japanese supplements usually provide this count in two pills per day. If one wishes to compare existing studies, 20 billion CFU/day is the most well-established starting point.

CFU stands for colony-forming units, a measure of viable microorganisms capable of forming colonies. Twenty billion CFU does not mean 20 billion milligrams or 20 billion bacteria of any kind; it refers to approximately 20 billion viable units of MCC1274. When choosing a product, verify the species, strain designation, and CFU count. A label that lists only Bifidobacterium breve or a high total bacterial count does not establish equivalence.

There is currently no evidence that 50 billion CFU per day is better than 20 billion CFU, and the effect of probiotics cannot be simply linearly calculated based on the number of bacteria. Existing randomized trials lasted 12, 16, or 24 weeks, with stronger memory results occurring at 16 weeks and MRI signals at 24 weeks. It is not a product that enhances memory or concentration the day it is taken, but the likely mode of action is more consistent with ingestion over several months.

Safety and Precautions

The short- and mid-term safety profile of MCC1274 in available human studies is generally favorable. The 2019 study found no apparent safety concerns related to the strain; No clinically significant blood test abnormalities, vital sign abnormalities, or strain-related serious adverse events were observed in the 16-week trial in 2020. The 2022 study recorded medical events such as lumbar compression fractures and mild constipation, but the researchers did not determine that these events were caused by MCC1274.

The short- and medium-term safety data for the average healthy adult at 20 billion CFU per day for several months are relatively stable, but other ingredients in specific commercial products still need to be confirmed separately. For example, some Japanese MCC1274 capsules contain milk ingredients and are not suitable for people with milk allergies. The safety of the strains themselves and the allergens in the product formulation are two separate issues.

• Check strains:Packaging should clearly say Bifidobacterium breve MCC1274 or B. breve A1
• Check the number of bacteria:Representative doses for existing cognitive trials are 20 billion CFU per day
• Check the recipe:Pay attention to allergens such as milk ingredients and other added ingredients
• Reasonable expectations:Existing studies observe continuous intake for 12 to 24 weeks, not immediate improvements in cognition
• Medical treatment priority:If significant or sustained cognitive decline has occurred, formal medical evaluation should be performed first

Not a Treatment or Preventive Drug

Although many trials included people with suspected mild cognitive impairment or mild cognitive decline, and some studies also observed improvements in memory, However, there was no significant advantage in the primary comparison among all subjects in 2019, and there were no significant between-group differences in 2022 ADAS-Jcog and MMSE total scores. A more reliable statement at this stage is that MCC1274 may help some people with mild cognitive decline maintain or improve certain cognitive functions, and it cannot be called a treatment for mild cognitive impairment.

There are currently no human trials proving that it can reduce the rate of progression from mild cognitive impairment to Alzheimer's disease or reduce the incidence of dementia. or reverse amyloid and tau pathology in humans. Aβ, neuroinflammation and memory improvement in animal experiments are mechanistic studies, It is not a substitute for clinical evidence for the prevention or treatment of Alzheimer's disease.

Research Independence and Functional Food Labeling

MCC1274 is a commercial strain developed by Morinaga Dairy. Key trials in 2019, 2020 and 2022 include researchers from the company, Some of the research is also supported by industry. Randomized, double-blind, placebo-controlled designs still have research value, but there is still a lack of multiple completely independent university or hospital teams. Repeat the verification for the same strength results. This is an important limitation when judging the reliability of evidence.

Related products on the Japanese market are functional food products, which can be labeled as helping healthy middle-aged and elderly people maintain some cognitive functions that decline with age. Mainly involves memory and spatial cognitive abilities. This type of label is not drug approval, nor does it mean that the product has been reviewed item by item for efficacy. It does not mean that it is approved for the diagnosis, treatment, or prevention of mild cognitive impairment and Alzheimer's disease.

Strength of the Current Evidence

The scores below are intended to provide a visual representation of human trials, animal mechanisms, and repeated validation and are not official ratings or medical conclusions.

Conclusion

The value of MCC1274 is that it connects specific bifidobacteria, intestinal metabolites, immune-inflammatory regulation, and cognitive function into a research line worthy of continued validation. The most commonly used regimen in human trials is 20 billion CFU per day for 12 to 24 weeks; the more stable positive signals are concentrated in immediate memory, delayed memory and spatial cognition.

At the same time, subsequent longer trials did not show an advantage between groups in ADAS-Jcog and MMSE total scores, and MRI results only showed signals for some indicators. Therefore, it can be regarded as a potential cognitive probiotic, but it cannot replace formal diagnosis and treatment, nor can it be claimed to prevent brain atrophy, Prevent Alzheimer's disease or treat mild cognitive impairment.